drugset / Trial / NCT00272753

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

NCT00272753

Phase 4 Completed 20 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three AMP provocation tests performed on one day

Timeline

Start
2004-04
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled
Subject Salbutamol Unknown 200 ug Inhaled

Indications